1. Home
  2. PGY vs GERN Comparison

PGY vs GERN Comparison

Compare PGY & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pagaya Technologies Ltd.

PGY

Pagaya Technologies Ltd.

HOLD

Current Price

$12.41

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.67

Market Cap

900.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PGY
GERN
Founded
2016
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
900.1M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
PGY
GERN
Price
$12.41
$1.67
Analyst Decision
Strong Buy
Buy
Analyst Count
8
7
Target Price
$34.50
$3.00
AVG Volume (30 Days)
5.5M
13.9M
Earning Date
02-09-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.93
N/A
Revenue
$1,301,360,000.00
$183,403,000.00
Revenue This Year
$18.57
$146.80
Revenue Next Year
$14.58
$30.21
P/E Ratio
$13.37
N/A
Revenue Growth
26.07
522.13
52 Week Low
$8.50
$1.04
52 Week High
$44.99
$2.84

Technical Indicators

Market Signals
Indicator
PGY
GERN
Relative Strength Index (RSI) 24.69 69.05
Support Level $12.05 $1.55
Resistance Level $15.51 $1.69
Average True Range (ATR) 1.34 0.09
MACD -0.72 0.02
Stochastic Oscillator 4.03 90.05

Price Performance

Historical Comparison
PGY
GERN

About PGY Pagaya Technologies Ltd.

Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: